Oxigene Plans Phase II Lung Cancer Trial
Posted on: Monday, 6 February 2006, 15:00 CST
Oxigene is planning a phase II clinical trial in the US evaluating its lead clinical candidate, Combretastatin A4P, in the treatment of stage IIIa/IIIb non small cell lung cancer.
The company will evaluate Combretastatin A4P (CA4P), in combination with concurrent chemo-radiotherapy, a widely accepted standard in the US for the treatment of unresectable stage IIIa/IIIb non small cell lung cancer (NSCLC).
The phase II clinical trial will initially enroll approximately 12 patients to assess the tolerability of the protocol and to establish the recommended dose of intravenously administered CA4P.
In other ongoing clinical trials, CA4P has been paired with chemotherapy or radiation therapy with no observed side effects beyond those typically experienced with either treatment.
The trial will then proceed to compare approximately 66 patients who will be split into an investigational group and an active control group.
"We believe this phase II clinical trial to be a key stepping stone in the path towards potential commercialization of CA4P for the treatment of NSCLC," commented Frederick Driscoll, president and CEO of Oxigene.
Source: Datamonitor
Related Articles
- Reportlinker Adds Innovations and Trends in Clinical Trials: Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
- EpiCept Announces Positive Clinical Data From EPC2407 Phase I Cancer Trial
- FDA Lifts Clinical Hold on Vion's Phase III Trial of Leukemia Drug
- Natrol Highlights Published Clinical Treatment Protocol Recommending Red Clover Isoflavones As a Safe Alternative to Hormone Replacement Therapy
- Novagali Pharma Announces Positive Vekacia(R) Clinical Results From Pivotal Phase III Trial in Vernal Keratoconjunctivitis
- Clinical Data Initiates Pivotal Phase III Trial for Novel Antidepressant
- Journal of Clinical Oncology Publishes Pivotal Phase III Study Reporting Superior Response Rate of ABRAXANE(TM) Compared With Taxol(R) in Women With Metastatic Breast Cancer(1)
- First Melanoma Patients Complete Treatment in Provectus Phase 1 Clinical Trial of PV-10
- Altus Pharmaceuticals Announces Completion of Clinical Testing in the Phase I Study of ALTU-238 - a Long-Acting Crystalline Formulation of Human Growth Hormone
- AVANIR Receives Special Protocol Assessment For Neurodex Neuropathic Pain Clinical Trial; Phase III Trial to Begin First Half of 2005
 |
 |
User Comments (0)
RSS Feeds